Literature DB >> 1886398

Serum osteocalcin levels in primary hyperparathyroidism.

P Pietschmann1, B Niederle, A Anvari, W Woloszczuk.   

Abstract

The serum levels of osteocalcin, a 49-amino-acid bone-matrix protein, have been found to be a specific biochemical parameter of bone formation. The aim of our study was to compare the sensitivity of serum osteocalcin levels with that of alkaline phosphatase in the evaluation of patients with primary hyperparathyroidism. In 40 patients with biochemically and histologically confirmed primary hyperparathyroidism, the serum levels of osteocalcin, intact parathyroid hormone, alkaline phosphatase, calcium, phosphorus, and creatinine were determined preoperatively. The serum levels of osteocalcin were elevated in 22 patients (55%), whereas the serum levels of alkaline phosphatase were increased in 18 patients (45%). In 10 patients (25%) the serum levels of osteocalcin, but not those of alkaline phosphatase, were increased, whereas in six patients the activity of alkaline phosphatase was high, but the serum osteocalcin levels were normal. When the biochemical data of the patients with increased serum osteocalcin levels were compared with those of the patients with serum osteocalcin levels within the normal range, the serum levels of intact parathyroid hormone and alkaline phosphatase were significantly increased in the group of patients with elevated serum osteocalcin levels. Our data indicate that serum osteocalcin levels might be a clinically useful additional parameter in the evaluation of patients with primary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1886398     DOI: 10.1007/bf02115782

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  13 in total

1.  Serum osteocalcin in primary hyperparathyroidism: short-term effect of surgery.

Authors:  S Minisola; L Scarnecchia; A Scarda; F Bigi; S Tabolli; C Valtorta; G Mazzuoli
Journal:  Miner Electrolyte Metab       Date:  1988

2.  Serum bone Gla-protein compared to bone histomorphometry in endocrine diseases.

Authors:  P D Delmas; L Malaval; M E Arlot; P J Meunier
Journal:  Bone       Date:  1985       Impact factor: 4.398

3.  Serum osteocalcin levels and bone alkaline phosphatase isoenzyme after oophorectomy and in primary hyperparathyroidism.

Authors:  J J Stĕpán; J Presl; P Broulík; V Pacovský
Journal:  J Clin Endocrinol Metab       Date:  1987-05       Impact factor: 5.958

4.  Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis.

Authors:  J P Brown; P D Delmas; L Malaval; C Edouard; M C Chapuy; P J Meunier
Journal:  Lancet       Date:  1984-05-19       Impact factor: 79.321

5.  New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease.

Authors:  P A Price; J G Parthemore; L J Deftos
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

6.  Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment.

Authors:  S E Papapoulos; M Frolich; A H Mudde; H I Harinck; H vd Berg; O L Bijvoet
Journal:  J Clin Endocrinol Metab       Date:  1987-07       Impact factor: 5.958

7.  Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry.

Authors:  P D Delmas; B Demiaux; L Malaval; M C Chapuy; C Edouard; P J Meunier
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

8.  Decreased serum osteocalcin levels in phenprocoumon-treated patients.

Authors:  P Pietschmann; W Woloszczuk; S Panzer; P Kyrle; J Smolen
Journal:  J Clin Endocrinol Metab       Date:  1988-05       Impact factor: 5.958

9.  Changes in plasma bone GLA protein during treatment of bone disease.

Authors:  L J Deftos; J G Parthemore; P A Price
Journal:  Calcif Tissue Int       Date:  1982-03       Impact factor: 4.333

10.  Osteocalcin and bone morphometric parameters in adults without bone disease.

Authors:  M Garcia-Carrasco; M Gruson; M C de Vernejoul; M A Denne; L Miravet
Journal:  Calcif Tissue Int       Date:  1988-01       Impact factor: 4.333

View more
  2 in total

Review 1.  Bone turnover in hyperparathyroidism.

Authors:  Katharina Kerschan-Schindl
Journal:  Wien Med Wochenschr       Date:  2012-07-18

2.  Decrease of serum calcium concentration and lost influence of calcium on parathyroid hormone release in a patient with primary hyperparathyroidism after treatment with diphosphonates.

Authors:  H Kotzmann; P Bernecker; T Svoboda; B Niederle; A Luger
Journal:  Calcif Tissue Int       Date:  1993-11       Impact factor: 4.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.